Program
tenapanor
Also written as “Tenapanor”, “AZD1722” and “KHK7791”.
Its studies are mostly in Hyperphosphatemia · Constipation · Breast Feeding · Kidney Failure, Chronic · Renal Insufficiency, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ardelyx | 272 open or running | phase 4since Jun 14, 2019 | Apr 20, 2011 | Feb 26, 2027phase 3 · NCT07382167 |
| Kyowa Kirin | 70 open or running | phase 3since Feb 16, 2021 | Jan 29, 2019 | none ahead |
Also a collaborator on its studies: AstraZeneca.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Apr 20, 2011.
- Mar 23, 2016Phase 3 study in Constipation Predominant Irritable Bowel SyndromeArdelyx · NCT02727751 · 312 enrolled · United States
- Jun 7, 20162 phase 1 studies in HealthyArdelyx · NCT02819687, NCT02796131
- Jan 19, 2018Phase 3 study in HyperphosphatemiaArdelyx · NCT03427125 · 1,559 enrolled · United States
- Jan 29, 2019Kyowa Kirin's first study: phase 2 study in HyperphosphatemiaNew to Kyowa KirinKyowa Kirin · NCT03831607 · 67 enrolled · Japan
- Jan 29, 2019Phase 3 study in HyperphosphatemiaArdelyx · NCT03824587 · 236 enrolled · United States
- Mar 4, 20192 phase 2 studies in HyperphosphatemiaKyowa Kirin · NCT03864458, NCT03864445
- Jun 14, 2019Phase 4 study in HyperphosphatemiaArdelyx · NCT03988920 · 172 enrolled · United States
- Sep 9, 2020Phase 4 study in HyperphosphatemiaArdelyx · NCT04549597 · 333 enrolled · United States
- Feb 16, 20214 phase 3 studies in HyperphosphatemiaKyowa Kirin · NCT04771780, NCT04767581, NCT04766398 and 1 more
- Nov 30, 2022Phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)Ardelyx · NCT05643534 · 180 enrolled · United States
- Mar 7, 2023Phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)Ardelyx · NCT05905926 · 150 planned · United States
- Dec 17, 2023Phase 1 study in Breast FeedingArdelyx · NCT06203444 · 7 enrolled · United States
- Aug 12, 2024Phase 2 study in Irritable Bowel Syndrome With Constipation (IBS-C)Ardelyx · NCT06553547 · 72 enrolled · United States
- Jan 26, 2026Phase 3 study in Chronic Idiopathic Constipation (CIC)Ardelyx · NCT07382167 · 692 planned · United States
Ahead
- Feb 26, 2027Primary completion: phase 3 study in Chronic Idiopathic Constipation (CIC)Ardelyx · NCT07382167
- Jul 2031Primary completion: phase 3 study in Irritable Bowel Syndrome With Constipation (IBS-C)Ardelyx · NCT05905926
TargetBeta
“Sodium/hydrogen exchanger 3 inhibitor”ChEMBL 37, by rule
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07382167Chronic Idiopathic Constipation (CIC) · United States | 3 | Recruiting | Ardelyx | Feb 26, 2027 | 692 |
| NCT06553547Irritable Bowel Syndrome With Constipation (IBS-C) · United States | 2 | Completed | Ardelyx | Jul 7, 2026 | 72 |
| NCT06203444Breast Feeding · United States | 1 | Completed | Ardelyx | May 30, 2024 | 7 |
| NCT05905926Irritable Bowel Syndrome With Constipation (IBS-C) · United States | 3 | By invitation | Ardelyx | Jul 2031 | 150 |
| NCT05643534Irritable Bowel Syndrome With Constipation (IBS-C) · United States | 3 | Completed | Ardelyx | Aug 20, 2026 | 180 |
| NCT04771780Hyperphosphatemia · Japan | 3 | Completed | Kyowa Kirin | Jun 27, 2022 | 213 |
| NCT04767581Hyperphosphatemia · Japan | 3 | Completed | Kyowa Kirin | Aug 10, 2021 | 165 |
| NCT04766398Hyperphosphatemia · Japan | 3 | Completed | Kyowa Kirin | Sep 27, 2021 | 169 |
| NCT04766385Hyperphosphatemia · Japan | 3 | Completed | Kyowa Kirin | Dec 1, 2021 | 54 |
| NCT04549597Hyperphosphatemia · United States | 4 | Completed | Ardelyx | Oct 13, 2021 | 333 |
| NCT03988920Hyperphosphatemia · United States | 4 | Completed | Ardelyx | Jun 26, 2021 | 172 |
| NCT03864458Hyperphosphatemia · Japan | 2 | Completed | Kyowa Kirin | Dec 10, 2019 | 207 |
| NCT03864445Hyperphosphatemia · Japan | 2 | Completed | Kyowa Kirin | Dec 3, 2019 | 47 |
| NCT03831607Hyperphosphatemia · Japan | 2 | Completed | Kyowa Kirin | Nov 26, 2019 | 67 |
| NCT03824587Hyperphosphatemia · United States | 3 | Completed | Ardelyx | Jul 17, 2019 | 236 |
| NCT03427125Hyperphosphatemia · United States | 3 | Completed | Ardelyx | Nov 15, 2019 | 1,559 |
| NCT02819687Healthy | 1 | Completed | Ardelyx | Mar 2011 | 80 |
| NCT02796131Healthy | 1 | Completed | Ardelyx | Oct 2011 | 105 |
| NCT02727751Constipation Predominant Irritable Bowel Syndrome · United States | 3 | Completed | Ardelyx | Oct 2017 | 312 |
| NCT02675998Hyperphosphatemia · United States | 3 | Completed | Ardelyx | Dec 2016 | 219 |
| NCT02686138Constipation Predominant Irritable Bowel Syndrome · United States | 3 | Completed | Ardelyx | Aug 2017 | 593 |
| NCT02621892Constipation Predominant Irritable Bowel Syndrome · United States | 3 | Completed | Ardelyx | Mar 2017 | 606 |
| NCT02346890Healthy · United States | 1 | Completed | Ardelyx | Apr 2013 | 16 |
| NCT02249936Healthy · United States | 1 | Completed | Ardelyx | Feb 2013 | 18 |
| NCT02226783Healthy Volunteers Food Interaction Study · United States | 1 | Completed | Ardelyx | Oct 2013 | 37 |
| NCT02140281Healthy Volunteers · United States | 1 | Completed | Ardelyx | Aug 2014 | 71 |
| NCT02140268Healthy Volunteers · United States | 1 | Completed | Ardelyx | Aug 2014 | 65 |
| NCT02081534Hyperphosphatemia · United States, Poland, Slovakia and more | 2 | Completed | Ardelyx | Nov 2014 | 162 |
| NCT02063386Healthy Volunteers · United Kingdom | 1 | Completed | Ardelyx | May 2014 | 26 |
| NCT02176252Healthy Volunteer · United States | 1 | Completed | Ardelyx | Dec 2013 | 83 |
| NCT01923428Constipation Predominant Irritable Bowel Syndrome · United States | 3 | Completed | Ardelyx | Oct 2014 | 356 |
| NCT01847092Renal Insufficiency, Chronic · United States | 2 | Completed | Ardelyx | Mar 2015 | 154 |
| NCT01764854Kidney Failure, Chronic · United States | 2 | Completed | Ardelyx | Oct 2013 | 88 |
| NCT01340053Constipation Predominant Irritable Bowel Syndrome · United States | 2 | Completed | Ardelyx | Dec 2011 | 186 |
How it is read
Names in the registry
- “Tenapanor”, 11 entries
- “AZD1722”, 8 entries
- “KHK7791”, 7 entries
- “RDX5791”, 3 entries
- “Tenapanor 50 MG”, 1 entry
Codes read as this program: AZD1722.
Conditions, from the studies’ own filings
- Hyperphosphatemia, 13 studies
- Constipation, 9 studies
- Breast Feeding, 1 study
- Kidney Failure, Chronic, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.